Dexmedetomidine vs Lignocaine for Reducing Intubation-Induced Hemodynamic Responses in Cardiac Surgery: A Randomized Controlled Trial

NCT07611890 | Recruiting Phase 4 DMC

• 1 other identifier: RIC/RERC/13/25
• Study Type: interventional
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

After confirming eligibility, written informed consent will be obtained by a trained team member who is not involved in assigning treatment or giving the study medication. Each participant will receive a unique study number to protect privacy. Participants will be randomly assigned to receive one of the study medications using a chance-based method.The study medication will be administered through a vein before placement of the breathing tube. Blood pressure and pulse rate will be measured before the procedure and at several time points after the breathing tube is inserted.

Conditions

Laryngoscopic Stress Response; Dexmedetomidine; Lignocaine

Keywords

Laryngoscopic stress response; Dexmedetomidine; Lignocaine; Cardiac surgery

Outcome Measures

Primary Outcomes (2)

• Mean Arterial Pressure

  It will be expressed in millimeters of mercury (mmHg) and measured using an arterial catheter immediately before intubation and then at 1,3,5 and 10 minutes after intubation.

• Heart Rate

  It will be expressed as number of heart beats per minute and measured using pulse oximeter immediately before intubation and then at 1,3,5 and 10 minutes after intubation.

Study Arms (2)

Group Dexmed

ACTIVE COMPARATOR

Drug: IV dexmedetomidine

Group Lignocaine

ACTIVE COMPARATOR

Drug: IV Lignocaine

Interventions

IV dexmedetomidine DRUG

0.5 Mcg/kg of Dexmedetomidine will be given 10 minutes before laryngoscopy

Group Dexmed

IV Lignocaine DRUG

Patients will be given 1.5 mg/kg of Lignocaine 3 minutes before laryngoscopy

Group Lignocaine

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• American Society of Anesthesiologists (ASA) physical status III-IV. Patients who are at risk of cardiovascular events

You may not qualify if:

• Patients with known hypersensitivity to dexmedetomidine and Lignocaine.
• Patients on medications that could interfere with the study (e.g., beta-blockers, calcium channel blockers).
• Pregnant or lactating women.
• Patients with a history of airway anomalies or difficult intubation.

Sponsors & Collaborators

• Rawalpindi Institute of Cardiology: lead

Study Sites (1)

Rawalpindi Institute of Cardiology

Rawalpindi, Punjab Province, 46000, Pakistan

RECRUITING

Related Publications (1)

• Dube S, Gosavi K, Admane G. Comparative study of Dexmedetomidine, Lignocaine and their combination for the attenuation of hemodynamic response during laryngoscopy and intubation [Internet]. Indian J Clin Anaesth. 2022 [cited 2026 May 21];9(1):27-31. Available from: https://doi.org/10.18231/j.ijca.2022.007

  BACKGROUND

MeSH Terms

Interventions

Dexmedetomidine; Lidocaine

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Officials

• Qudsia Anjum, MBBS,FCPS

  Rawalpindi Institute of Cardiology

  STUDY CHAIR

Central Study Contacts

Namrah Zujaj, MBBS

CONTACT

+92 305 2636980; zujajnamrah20@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: May 21, 2026
• First Posted: May 28, 2026
• Study Start: May 21, 2026
• Primary Completion (Estimated): August 21, 2026
• Study Completion (Estimated): August 21, 2026
• Last Updated: May 28, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)